Thursday Mar 23, 2023

FDA Approves Chiesi’s Lamzede® (velmanase alfa-tycv) for Alpha-Mannosidosis Treatement in USA

According to Biospace, the U.S. Food and Drug Administration (FDA) has authorized Lamzede® (velmanase alfa-tycv) for the management of alpha-mannosidosis (AM) in both adult and pediatric patients with non-central nervous system symptoms. This news was made public by Chiesi Global Rare Diseases, a division of Chiesi Farmaceutici S.p.A., a global healthcare group with a research-focused […]

Back to Top